Find Funding Opportunities

This funding opportunity announcement invites research on the mechanism(s) by which abnormal proteins spread throughout the nervous systems of patients with Frontotemporal Dementia and/or Lewy Body Dementia. Applications that move beyond a focus on one mechanisms of spread to consider how spreading might proceed in the context of multiple proteinopathies, multiple cell/circuit types, and multiple pathways are of particular interest.

NIH is issuing this RFA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the NIH provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this RFA is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Notice Special Interest NOSI): Platform Trials Thrombectomy Acute Stroke Treatment Notice Number: NOT-NS-20-095 Key Dates Release Date: August 5, 20 First Available Due Date: October 14, 2020 Expiration Date: July 15, 2021 Related Announcements PAR-20-285 - NIH StrokeNet Clinical Trials Biomarker Studies Stroke Treatment, Recovery, Prevention UG3/UH3 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose NINDS issuing Notice Special Interest applications establish master protocol conduct platform trials treatments ischemic stroke due large vessel occlusion. Master protocols should incorporate advanced clinical trial methodologies such as, not limited to, Bayesian modeling, response adaptive randomization, shared controls, the ability treatment arms enter, leave, be combined. Master protocols must designed allow future addition trial questions. Strong representation expertise the neurology, neurosurgery, interventional communities required such multi-disciplinary approach will expected applicants. Research Objectives Recent pivotal interventional trials patients ischemic stroke due large vessel occlusion shown mechanical thrombectomy be highly beneficial certain groups patients to 24 hours after last known well. However, questions remain the potential benefit harm thrombectomy specific subgroups patients certain ischemic stroke phenotypes. Also interest considerations such pre-hospital care peri-procedural management strategies. Further, success mechanical thrombectomy raises possibility a new era neuroprotection patients large vessel ischemic stroke. Promising neuroprotectants failed trials predated successful reperfusion, well newer agents have potential remain untested, ripe consideration this new environment. NINDS interested master protocols enable platform trials answer above questions using seamless rolling approach. Trials further refine patient groups do do benefit mechanical thrombectomy, using management approaches, also open door testing neuroprotectant strategies an efficient, timely, cost-effective manner. Clinical study protocols consist acute short-term procedures are deemed Non-Significant Risk NSR) an Institutional Review Board IRB), Significant Risk SR) studies require Investigational Device Exemption IDE) the FDA. Evidence contact appropriate U.S. regulatory bodies e.g., IRB NSR studies and/or FDA the form either Pre-Submission meeting IDE submission SR studies recommended. Applicants must the resources ability do work without critically impacting high-priority, on-going NINDS research programs. Investigators planning submit application response the NOSI strongly encouraged contact program officer listed below discuss proposed project. Application Submission Information notice applies due dates or after October 14, 2020 subsequent receipt dates through July 14, 2021.  Applications this initiative must submitted using following funding opportunity announcement FOA) any reissues these announcement through expiration date this notice: PAR-20-285 - NIH StrokeNet Clinical Trials Biomarker Studies Stroke Treatment, Recovery, Prevention UG3/UH3 Clinical Trial Optional) instructions the SF424 R&R) Application Guide the funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include “NOT-NS-20-095” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications non-responsive terms this NOSI be be considered the NOSI initiative. Applications nonresponsive terms this NOSI will not considered the NOSI initiative. Inquiries Please direct inquiries the Scientific/Research, Peer Review, Financial/Grants Management contacts Section VII the listed funding opportunity announcements.

This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers

The National Institute of Neurological Disorders and Stroke (NINDS) is soliciting applications for a Human Biospecimen and Data Repository for Biomarkers Research ("Biomarkers Repository") in Neurological Disorders. Collaborative teams combining expertise in neuroscience, biomarkers, biospecimen handling, and data management are encouraged. Experience in biomarker research, such as evaluation of batch effects, protocol development, and analyte quality control measures, is expected. Successful applications will include a detailed description of 1) Administrative Structure, 2) Research and Resource Plan, and 3) Data Management and Web-Based activities.

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

The purpose of this FOA isto develop tools and technologies to conduct cientifically rigorous, ethical, efficient, and cost-effective research infrastructure that supports germline and somatic transgenic and gene editing studies in the common marmoset (Callithrix jacchus). These studies should to answer crucial scientific questions that require genetic perturbation in a non-human primate model organism with the aim of supporting BRAIN goals of understanding the brain in health an disease.

This Funding Opportunity Announcement (FOA) requests Exploratory Grant (P20) applications for the planning and initiation of collaborative activities to advance Parkinson's Disease (PD) research. The goal of this FOA is to convene new transdisciplinary research consortia and formalize the multi-institutional organizational and investigational structure necessary to resolve an essential challenge in Parkinson's disease (PD) through a subsequent NINDS Udall Center without Walls (CWOW) approach. The most compelling applications will: (i) identify a fundamental PD research priority; (ii) build an exemplary research consortium; (iii) gather supportive preliminary data; and (iv) demonstrate exceptional potential to pursue a targeted strategy to remove a critical impediment blocking advancement of the understanding and treatment of PD. The stated challenge and related research feasibility projects will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the central PD research challenge. To foster the development of innovative research collaborations, this FOA will provide support for new research consortia only; continuation of established projects and teams will not be supported. Proposed consortia must include the optimal combination of specialized expertise required to resolve the stated challenge using a goal-driven approach. The Program Director/Principal Investigator (PD/PI) must be eminently qualified to provide visionary scientific leadership and effective oversight of consortium administrative activities. Participating investigators should be recognized as world-class experts in their fields. Teams must be anchored by at least one PD researcher. To maximize potential for new insights and incorporation of cutting-edge approaches, consortia will actively integrate at least one investigator with primary expertise in another, complementary research area. The applicant inst